Synthesis and calpain inhibitory activity of peptidomimetic compounds with constrained amino acids at the P2 position
Graphical abstract
Peptidomimetic with P2 α-aminocyclopentane carboxylic acid. μ-Calpain inhibition, Ki = 1.94 μM, cathepsin B inhibition, Ki = 0.88 μM. Peptidomimetic with P2 α,α′-diethylglycine. μ-Calpain inhibition, Ki = 0.08 μM, cathepsin B inhibition, Ki = 2.91 μM.
Section snippets
Acknowledgment
This work was supported by NIH Grant R15 HL083968-01 to I.O.D.
References and notes (23)
- et al.
Cell
(2005) - et al.
J. Biol. Chem.
(1997) - et al.
Trends Pharm. Sci.
(1994) - et al.
Adv. Pharm.
(1997) - et al.
Exp. Neurol.
(1999) - et al.
Bioorg. Med. Lett.
(2000) - et al.
J. Mol. Biol.
(2004) - et al.
Bioorg. Med. Chem. Lett.
(2003) - et al.
Physiol. Rev.
(1991) - et al.
Biol. Chem.
(1995)
Biochem. J.
Cited by (6)
NCS-1 is a regulator of calcium signaling in health and disease
2018, Biochimica et Biophysica Acta - Molecular Cell ResearchCitation Excerpt :With the known cleavage site of NCS-1 [24], a drug based on the amino acid sequence could function as a competitive inhibitor and thus prevent cleavage of native NCS-1. This approach was shown to be successful in cell based assays [92,130,131]. These results highlight the importance of calpain in the development of CIPN and suggest that calpain inhibition, if specificity could be achieved, is a promising approach for prevention of CIPN.
Calpains and neuronal damage in the ischemic brain: The swiss knife in synaptic injury
2016, Progress in NeurobiologyDevelopment of α-helical calpain probes by mimicking a natural protein-protein interaction
2012, Journal of the American Chemical SocietyCalpain inhibitors: A survey of compounds reported in the patent and scientific literature
2011, Expert Opinion on Therapeutic PatentsPeptidyl α-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors
2010, Journal of Medicinal Chemistry